A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors

48Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The aim of the study was to determine the safety profile, pharmacokinetics and potential drug interactions of the angiogenesis inhibitor ABT-510 combined with gemcitabine - cisplatin chemotherapy in patients with solid tumors. Patients and methods: Patients with advanced solid tumors received gemcitabine 1250 mg/m2 intravenously (i.v.) on days 1 and 8 and cisplatin 80 mg/m2 on day 1 of a 3-week cycle in combination with ABT-510. ABT-510 was administered subcutaneously twice daily at doses of 50 mg or 100 mg. Plasma samples for pharmacokinetics were obtained on days 1 (gemcitabine, cisplatin as single agents), 15 (ABT-510 as single agent) and 22 (gemcitabine, cisplatin and ABT-510 as combination). Results: Thirteen patients received ABT-510 as either 50 mg b.i.d. (seven patients) or 100 mg b.i.d. (six patients) in combination with gemcitabine - cisplatin. The most common reported adverse events reflected the known toxicity profile induced by gemcitabine - cisplatin without ABT-510. One episode of hemoptysis occurred in a patient with non-small-cell lung cancer (NSCLC) after 13 days of treatment. No clinically significant pharmacokinetic interactions between ABT-510, gemcitabine and platinum were observed. Three partial responses were observed in 12 evaluable patients (one head and neck cancer, one melanoma and one NSCLC). Conclusions: Combining ABT-510 at doses of 50 mg and 100 mg with gemcitabine - cisplatin is feasible. Pharmacokinetic interactions were not observed and adding ABT-510 does not appear to increase toxicity. © 2006 Oxford University Press.

References Powered by Scopus

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

9687Citations
N/AReaders
Get full text

Tumor Angiogenesis: Therapeutic Implications

9242Citations
N/AReaders
Get full text

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

5017Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Regulation of nitric oxide signalling by thrombospondin 1: Implications for anti-angiogenic therapies

246Citations
N/AReaders
Get full text

CD36: Implications in cardiovascular disease

205Citations
N/AReaders
Get full text

Thrombospondin-based antiangiogenic therapy

121Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Gietema, J. A., Hoekstra, R., de Vos, F. Y. F. L., Uges, D. R. A., van der Gaast, A., Groen, H. J. M., … Eskens, F. A. L. M. (2006). A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Annals of Oncology, 17(8), 1320–1327. https://doi.org/10.1093/annonc/mdl102

Readers over time

‘10‘12‘15‘16‘18‘19‘20‘21‘22‘23‘2402468

Readers' Seniority

Tooltip

Researcher 9

60%

PhD / Post grad / Masters / Doc 5

33%

Professor / Associate Prof. 1

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

44%

Agricultural and Biological Sciences 5

31%

Engineering 2

13%

Business, Management and Accounting 2

13%

Save time finding and organizing research with Mendeley

Sign up for free
0